CETUXIMAB (ERBITUX) IN COMBINATION WITH CISPLATIN OR CARBOPLATIN AND 5-FLUOROURACIL IN THE FIRST LINE TREATMENT OF SUBJECTS WITH RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (EXTREME):